Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation

Australian and New Zealand Journal of Psychiatry

Volumn 51, Issue 1, 2017, Pages 55-64

  Cusin, Cristina ^a   Ionescu, Dawn Flosnik ^a   Pavone, Kara Jean ^a   Akeju, Oluwaseun ^a   Cassano, Paolo ^a   Taylor, Norman ^a   Eikermann, Matthias ^a   Durham, Kelley ^a   Swee, Michaela Ballentyne ^a   Chang, Trina ^a   Dording, Christina ^a   Soskin, David ^b   Kelley, John ^a,c   Mischoulon, David ^a   Brown, Emery Neal ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Natividad Medical Center   (United States)

^c ENDICOTT COLLEGE   (United States)

Author keywords

antidepressant; depression; ketamine; Major depressive disorder; treatment resistant

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; CLONAZEPAM; DESVENLAFAXINE; DEXAMPHETAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; KETAMINE; LAMOTRIGINE; LISDEXAMFETAMINE; LITHIUM; LORAZEPAM; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENELZINE; QUETIAPINE; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VILAZODONE; ZOLPIDEM; ANTIDEPRESSANT AGENT;

ADULT; AMNESIA; ARTICLE; ATYPICAL DEPRESSION; BURSITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTUSION; COUGHING; CRYING; DEPERSONALIZATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELEVATED BLOOD PRESSURE; EPISTAXIS; FATIGUE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; MALE; MELANCHOLIA; MIDDLE AGED; NAUSEA; OPEN STUDY; OUTPATIENT; OXYGEN SATURATION; PANIC; PSYCHOPHARMACOTHERAPY; PULSE RATE; RELAPSE; REMISSION; REPEATED DRUG DOSE; SIDE EFFECT; SINUS CONGESTION; SOMNOLENCE; TENDINITIS; TINNITUS; TREATMENT RESISTANT DEPRESSION; URINARY HESITANCY; VISUAL DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG SYNERGISM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85008682134     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867416631828     Document Type: Article

References (33)

1. aan het Rot M, Collins KA, Murrough JW, et al. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 67: 139-145.
2. Beck AT, Guth D, Steer RA, et al. (1997) Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behavior Research and Therapy 35: 785-791.
3. Berman RM, Cappiello A, Anand A, et al. (2000) Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47: 351-354.
4. Bremner JD, Krystal JH, Putnam FW, et al. (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). Journal of Trauma Stress 11: 125-136.
5. Brown EN, Purdon PL, Van Dort CJ, (2011) General anesthesia and altered states of arousal: A systems neuroscience analysis. Annual Review of Neuroscience 34: 601-628.
6. Chandler GM, Iosifescu DV, Pollack MH, et al. (2010) RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neuroscience & Therapeutics 16: 322-325.
7. Crown WH, Finkelstein S, Berndt ER, et al. (2002) The impact of treatment-resistant depression on health care utilization and costs. Journal of Clinical Psychiatry 63: 963-971.
8. Diamond PR, Farmery AD, Atkinson S, et al. (2014) Ketamine infusions for treatment resistant depression: A series of 28 patients treated weekly or twice weekly in an ECT clinic. Journal of Psychopharmacology 28: 536-544.
9. Diazgranados N, Ibrahim L, Brutsche NE, et al. (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 67: 793-802.
10. Endicott J, Nee J, Harrison W, et al. (1993) Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin 29: 321-326.
11. Fava M, Iosifescu DV, Pedrelli P, et al. (2009) Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychotherapy and Psychosomatics 78: 91-97.
12. First MB, Spitzer RL, Gibbon M, et al. (1997) Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press.
13. Galvez V, O'Keefe E, Cotiga L, et al. (2014) Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: A case report. Biological Psychiatry 76: e1-e2.
14. Guy W, (1976) ECDEU Assessment Manual for Psychopharmacology (revised). Bethesda, MD: National Institute of Mental Health.
15. Hamilton M,. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 23: 56-62.
16. Ibrahim L, Diazgranados N, Franco-Chaves J, et al. (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37: 1526-1533.
17. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. (2011) Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Progress in Neuropsychopharmacology & Biological Psychiatry 35: 1155-1159.
18. Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. (2014) Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. Journal of Clinical Psychiatry 75: e932-e938.
19. Kessler RC, Berglund P, Demler O, et al. (2003) The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289: 3095-3105.
20. Mrazek DA, Hornberger JC, Altar CA, et al. (2014) A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatric Services 65: 977-987.
21. Murrough JW, Iosifescu DV, Chang LC, et al. (2013a) Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry 170: 1134-1142.
22. Murrough JW, Perez AM, Pillemer S, et al. (2013b) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry 74: 250-256.
23. Nelson JC, Papakostas GI, (2009) Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. American Journal of Psychiatry 166: 980-991.
24. Overall JE, Gorham DR, (1962) The Brief Psychiatric Rating Scale. Psychological Reports 10: 790-812.
25. Posner K, Brown GK, Stanley B, et al. (2011) The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry 168: 1266-1277.
26. Rabkin JG, Markowitz JS, Ocepek-Welikson K, et al. (1992) General versus systematic inquiry about emergent clinical events with SAFTEE: Implications for clinical research. Journal of Clinical Psychopharmacology 12: 3-10.
27. Rasmussen KG, Lineberry TW, Galardy CW, et al. (2013) Serial infusions of low-dose ketamine for major depression. Journal of Psychopharmacology 27: 444-450.
28. Rush AJ, Warden D, Wisniewski SR, et al. (2009) STAR∗D: Revising conventional wisdom. CNS Drugs 23: 627-647.
29. Shiroma PR, Johns B, Kuskowski M, et al. (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. Journal of Affective Disorders 155: 123-129.
30. Sos P, Klirova M, Novak T, et al. (2013) Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinology Letters 34: 287-293.
31. Trivedi MH, Rush AJ, Ibrahim HM, et al. (2004) The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychological Medicine 34: 73-82.
32. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biological Psychiatry 71: 939-946.
33. Zarate CA Jr, Singh JB, Carlson PJ, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63: 856-864.